Roughly 1 in 20 people with non-small cell lung cancer carries a KRAS G12D mutation, and once their disease progresses past platinum chemotherapy and a checkpoint inhibitor, the next step is docetaxel, a drug the FDA approved for that setting in 2000. Astellas is now running a 356-patient randomized Phase 3 trial to find out whether setidegrasib, a targeted protein degrader designed to physically eliminate the KRAS G12D protein from cancer cells, can beat that quarter-century-old standard. The first patient was dosed this week.
The trial design is straightforward: open-label, setidegrasib versus docetaxel, in patients with locally advanced or metastatic KRAS G12D-mutated NSCLC whose disease moved through both platinum chemotherapy and a checkpoint inhibitor. Dual primary endpoints are progression-free survival by blinded independent central review and overall survival. Both are needed because PFS alone in second-line NSCLC has not reliably predicted OS benefit, and regulators increasingly want to see the harder number.
The mechanism matters here. Existing approved KRAS inhibitors target the G12C substitution specifically; neither sotorasib nor adagrasib covers G12D, leaving this patient subgroup without a targeted option. Setidegrasib takes a different approach entirely: rather than occupying the mutant protein’s binding pocket, it recruits an E3 ligase to tag the KRAS G12D protein for degradation by the cell’s own machinery. Early clinical evidence published in the New England Journal of Medicine in March 2026 showed antitumor activity and a manageable safety profile across KRAS G12D-mutated solid tumors, which is what justified advancing to Phase 3 in NSCLC now. This is the second Phase 3 study of setidegrasib Astellas has opened within six months, following a front-line pancreatic ductal adenocarcinoma trial that started in April 2026.
Translational data from setidegrasib’s Phase 1 pancreatic cancer study, covering response mechanisms, resistance patterns, and potential combination strategies, will be presented at the AACR Conference on Pancreatic Cancer starting September 25. Those data, led by Wungki Park of Memorial Sloan Kettering, are worth watching: resistance mechanisms identified in pancreatic KRAS G12D disease will likely inform how the NSCLC trial interprets its own signals, particularly if the OS curve splits late or not at all.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
